NIBEC Valuation

Is A138610 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A138610 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A138610's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A138610's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A138610?

Key metric: As A138610 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A138610. This is calculated by dividing A138610's market cap by their current revenue.
What is A138610's PS Ratio?
PS Ratio	7.9x
Sales	₩19.41b
Market Cap	₩152.94b

A138610 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.8x
Enterprise Value/EBITDA	104x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A138610's PS Ratio compare to its peers?

The above table shows the PS ratio for A138610 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	16x
A217730 Kangstem Biotech	11.2x	n/a	₩148.5b
A084990 Helixmith	44x	n/a	₩139.5b
A251120 BIO-FD&CLtd	7.4x	28.9%	₩118.3b
A092040 Amicogen	1.3x	n/a	₩206.7b
A138610 NIBEC	7.9x	n/a	₩152.9b

Price-To-Sales vs Peers: A138610 is good value based on its Price-To-Sales Ratio (7.9x) compared to the peer average (16x).

Price to Sales Ratio vs Industry

How does A138610's PS Ratio compare vs other companies in the KR Biotechs Industry?

26 Companies	Price / Sales	Estimated Growth	Market Cap
A006280 GC Biopharma	1x	9.0%	US$1.15b
A096530 Seegene	2.7x	15.7%	US$765.97m
A086900 Medy-Tox	3.7x	14.5%	US$635.71m
A005250 Green Cross Holdings	0.3x	n/a	US$474.66m

26 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: A138610 is good value based on its Price-To-Sales Ratio (7.9x) compared to the KR Biotechs industry average (8.8x).

Price to Sales Ratio vs Fair Ratio

What is A138610's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A138610 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A138610's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Bioneer

₩521.4b

Operates as a biotechnology company in South Korea, the Americas, Europe, Asia, Africa, and internationally.

A064550

₩20,550.00

1.5%

-31.5%

Medy-Tox

₩869.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,900.00

0.5%

-41.1%

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩259,000.00

-5.3%

67.2%